The present study investigated the efficacy potential of HER2‐targeted NIR‐PIT using trastuzumab‐IRDye700DX conjugate (Tra‐IR700) in HER2‐positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.